Evidence map›Paper›PMID 39681749›Full record

ArticleInternational journal of clinical oncology2025

Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.

Jun Nagayama, Satoshi Inoue, Hiroki Sai, Akira Hayakawa, Yuri Yuguchi, Tomohide Suzuki, Hirotaka Matsui, Takuma Yuba, Koya Morishita, Shusuke Akamatsu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jun NagayamaDepartment of Urology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. j.nagayama@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0001-6239-2917
Satoshi InoueDepartment of Urology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
Hiroki SaiDepartment of Urology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
Akira HayakawaDepartment of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Yuri YuguchiDepartment of Urology, Chukyo Hospital, Nagoya, Japan.
Tomohide SuzukiDepartment of Urology, Nagoya Medical Center, Nagoya, Japan.
Hirotaka MatsuiDepartment of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan.
Takuma YubaDepartment of Urology, Kariya Toyota General Hospital, Kariya, Japan.
Koya MorishitaDepartment of Urology, Komaki Municipal Hospital, Komaki, Japan.
Shusuke AkamatsuDepartment of Urology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment-related skin reactions (TRSRs) induced by enfortumab vedotin (EV) targeting nectin-4 are among the most common adverse events. However, their association with survival and treatment response is poorly understood.

methodsWe retrospectively identified patients who received EV from December 2021 to April 2023 at Nagoya University Hospital and its affiliated facilities and extracted clinical data from their medical records. We evaluated cancer-specific survival (CSS) and progression-free survival (PFS) as survival outcomes and overall response rate (ORR) and disease control rate (DCR) as treatment responses between patients with and without TRSRs.

resultsIn total, 67 eligible patients were identified. Thirty-four patients experienced TRSRs, and the remaining 33 did not experience TRSRs. The median follow-up period was 8 months. Patients in the TRSRs group demonstrated significantly longer median CSS (15 vs. 8 months; p = 0.003) and median PFS (10 vs. 5 months; p < 0.001) than the non-TRSRs. Regarding treatment response, the patients in the TRSRs group showed a favorable, albeit nonsignificant, treatment response trend compared with those in the non-TRSRs group (ORR, 73.5% vs. 51.5%; p = 0.107; DCR, 91.2 % vs. 81.8%; p = 0.444).

conclusionsPatients with TRSRs demonstrated more prolonged survival and superior treatment responses to EV treatment. The role of TRSR as a surrogate marker of EV's efficacy should be further explored in prospective and sufficiently powered studies.

Indexed as

Antineoplastic Agents, ImmunologicalDrug EruptionsAdultAgedAged, 80 and overCell Adhesion MoleculesFemaleHumansMaleMiddle AgedNectinsProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalCell Adhesion MoleculesNECTIN4 protein, humanNectinsAdverse effectsBladder cancerEnfortumab vedotinSkin rashUrothelial carcinoma

Identifiers

PMID39681749
PMCPMC11785594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.